Journal of the American College of Surgeons
Volume 205, Issue 4 , Pages 546-557 , October 2007

Selective Administration of Prophylactic Octreotide During Pancreaticoduodenectomy: A Clinical and Cost-Benefit Analysis in Low- and High-Risk Glands

Abstract presented at the American College of Surgeons 92nd Annual Clinical Congress, Surgical Forum, Chicago, IL, October 2006.

Received 15 February 2007 ,Accepted 9 May 2007.

References 

  1. Ho CK, Kleeff J, Friess H, Buchler MW. Complications of pancreatic surgery. HPB. 2005;7:99–108
  2. Lin JW, Cameron JL, Yeo CJ, et al. Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg. 2004;8:951–959
  3. Bartoli FG, Arnone GB, Ravera G, Bachi V. Pancreatic fistula and relative mortality in malignant disease after pancreaticoduodenectomy (Review and statistical meta-analysis regarding 15 years of literature). Anticancer Res. 1991;11:1831–1848
  4. Tsiotos GG, Farnell MB, Sarr MG. Are the results of pancreatectomy for pancreatic cancer improving?. World J Surg. 1999;23:913–919
  5. Bassi C, Falconi M, Salvia R, et al. Management of complications after pancreaticoduodenectomy in a high volume centre: Results on 150 consecutive patients. Dig Surg. 2001;18:453–458
  6. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10–15
  7. Poon RT, Lo SH, Fong D, et al. Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am J Surg. 2002;183:42–52
  8. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg. 1997;226:248–257
  9. Balcolm JH, Rattner DW, Warshaw AL, et al. Ten-year experience with 733 pancreatic resections: Changing indications, older patients, and decreasing length of hospitalization. Arch Surg. 2001;136:391–398
  10. Gouma DJ, van Geenen RC, van Gulik TM, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg. 2000;232:786–795
  11. Pratt WB, Maithel SK, Vanounou T, et al. Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. Ann Surg. 2007;245:443–451
  12. Pratt WB, Maithel SK, Vanounou T, et al. Postoperative pancreatic fistulas are not equivalent after proximal, distal, and central pancreatectomy. J Gastrointest Surg. 2006;10:1264–1279
  13. Buchler M, Friess H, Klempa I, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg. 1992;163:125–130
  14. Pederzoli P, Bassi C, Falconi M, Camboni MG. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Br J Surg. 1994;81:265–269
  15. Rosenberg L, MacNeil P, Turcotte L. Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection. J Gastrointest Surg. 1999;3:225–232
  16. Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997;226:632–641
  17. Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? (Results of a prospective randomized placebo-controlled trial). Ann Surg. 2000;232:419–429
  18. de la Medina A, Sarr MG. Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection. HPB. 2006;13:190–193
  19. Barnett SP, Hodul PJ, Creech S, et al. Octreotide does not prevent postoperative pancreatic fistula or mortality following pancreaticoduodenectomy. Am Surg. 2004;70:222–227
  20. Gyr KE, Meier R. Pharmacodynamic effects of sandostatin in the gastrointestinal tract. Digest. 1993;54(Suppl 1):14–19
  21. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35:S1–S4
  22. Henegouwen MI, Gulik TM, Akkermans LMA, et al. The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers. Gut. 1997;41:758–762
  23. Konstadoulakis MM, Filippakis GM, Lagoudianakis E, et al. Intraarterial bolus octreotide administration during Whipple procedure in patients with fragile pancreas: a novel technique for safer pancreaticojejunostomy. J Surg Oncol. 2005;89:268–272
  24. Foitzik T, Gock M, Schramm C, et al. Octreotide hardens the pancreas. Langenbecks Arch Surg. 2006;391:108–112
  25. Klempa J, Schwedes U, Usadel KH. Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin. Chirurg. 1979;50:427–431
  26. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: An international study group (ISGPF) definition. Surgery. 2005;138:8–13
  27. Matsusue S, Takeda H, Nakamura Y, et al. A prospective analysis of factors influencing pancreaticojejunostomy performed using a single method, in 100 consecutive pancreaticoduodenectomies. Surg Today. 1998;28:719–726
  28. Yeh TS, Jan YY, Jeng LB, et al. Pancreaticojejunal anastomotic leak after pancreaticoduodenectomy—multivariate analysis of perioperative risk factors. J Surg Res. 1997;67:119–125
  29. Al Sharaf C, Ishe I, Dawiskiba S, Andren-Sandberg A. Characteristics of the gland remant predict complication after subtotal pancreaticoduodenectomy. Dig Surg. 1997;14:101–106
  30. Sato N, Yamaguchi K, Chijiiwa K, Tanaka M. Risk analysis of pancreatic fistula after pancreatic head resection. Arch Surg. 1998;133:1094–1098
  31. Vanounou T, Pratt WB, Fischer JE, et al. Deviation Based Cost Modeling (DBCM): a generalizable model to evaluate the clinical and economic impact of clinical pathways. J Am Coll Surg. 2007;204:570–579
  32. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213
  33. DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg. 2006;244:931–939
  34. Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. Br J Surg. 1991;78:356–360
  35. Bloom SR, Mortimer CH, Thorner MO, et al. Inhibition of gastrin- and gastric acid secretion by growth hormone release inhibiting hormone. Lancet. 1974;2:1106–1109
  36. Raptis S, Schlegel W, Lehmann E, et al. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metabolism. 1978;27:1321–1328

 Competing Interests Declared: None.

 This research was conducted with support from the Clinical Research Fellowship Program at Harvard Medical School offered by the Doris Duke Charitable Foundation and the Harvard PASTEUR Program and Office of Enrichment Programs.

PII: S1072-7515(07)00629-1

doi: 10.1016/j.jamcollsurg.2007.05.011

Journal of the American College of Surgeons
Volume 205, Issue 4 , Pages 546-557 , October 2007

Article Tools

* Image Usage & Resolution